Technical Analysis for IMMU - Immunomedics, Inc.

Grade Last Price % Change Price Change
grade B 14.94 3.97% 0.57
IMMU closed up 3.97 percent on Friday, August 16, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Flat
See historical IMMU trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
180 Bullish Setup Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
20 DMA Resistance Bearish 3.97%
MACD Bearish Signal Line Cross Bearish 3.97%
Down 3 Days in a Row Weakness 3.97%
Fell Below 20 DMA Bearish 0.27%
NR7 Range Contraction 0.27%
20 DMA Support Bullish -2.67%

Older signals for IMMU ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company's products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with Nycomed GmbH and UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Biotechnology Biopharmaceutical Cancer Immunology Treatment Of Cancer Monoclonal Antibodies Pharmacology Serious Diseases Pancreatic Cancer Non Hodgkin Lymphoma Humanized Antibody Lupus NHL Leukemias Cd20 Milatuzumab Treatment Of Lupus Treatment Of Non Hodgkin Lymphoma Treatment Of Pancreatic Cancer
Is IMMU a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 26.99
52 Week Low 11.55
Average Volume 1,885,589
200-Day Moving Average 16.1696
50-Day Moving Average 14.1804
20-Day Moving Average 14.9225
10-Day Moving Average 14.869
Average True Range 0.696
ADX 18.53
+DI 23.4494
-DI 22.6939
Chandelier Exit (Long, 3 ATRs ) 13.962
Chandelier Exit (Short, 3 ATRs ) 15.398
Upper Bollinger Band 15.9483
Lower Bollinger Band 13.8967
Percent B (%b) 0.51
BandWidth 13.748367
MACD Line 0.1343
MACD Signal Line 0.1749
MACD Histogram -0.0405
Fundamentals Value
Market Cap 1.66 Billion
Num Shares 111 Million
EPS -1.47
Price-to-Earnings (P/E) Ratio -10.16
Price-to-Sales 396.34
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.07
Resistance 3 (R3) 15.97 15.49 15.88
Resistance 2 (R2) 15.49 15.20 15.54 15.82
Resistance 1 (R1) 15.21 15.02 15.35 15.32 15.76
Pivot Point 14.73 14.73 14.80 14.78 14.73
Support 1 (S1) 14.46 14.44 14.60 14.56 14.12
Support 2 (S2) 13.98 14.27 14.03 14.06
Support 3 (S3) 13.70 13.98 14.00
Support 4 (S4) 13.81